KNSA

Business Context and Reporting Period

Company: Kiniksa Pharmaceuticals International, Plc (KNSA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Kiniksa is a biopharmaceutical company focused on cardiovascular indications. Its primary commercial product is ARCALYST (rilonacept), approved for recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). The company is also developing KPL-387 (recurrent pericarditis) and KPL-1161 (pre-clinical). In February 2025, the company announced the discontinuation of abiprubart development and the termination of its license agreement for mavrilimumab.

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The 2023 net income included a significant non-cash deferred tax benefit of $33.8 million. The 2024 net loss reflects increased operating expenses and a tax provision of $7.0 million.

Material Changes vs. Prior Period

• Revenue Growth: Product revenue surged 79% to $417.0 million, driven by increased patient enrollment for ARCALYST. Conversely, license revenue dropped 83% to $6.2 million due to the lack of large upfront payments or milestone achievements compared to 2023.
• Expense Increases:
  • Collaboration Expenses: Increased 127% to $128.3 million, primarily due to higher profit-sharing payments to Regeneron resulting from increased ARCALYST sales.
  • Cost of Goods Sold (COGS): Increased 82% to $60.9 million, driven by higher sales volume and $12.6 million in costs related to the technology transfer of ARCALYST manufacturing.
  • R&D Expenses: Increased 47% to $111.6 million, largely due to a $18.5 million write-off of prepayments for abiprubart manufacturing and continued development of KPL-387.
  • Selling, General & Administrative (SG&A): Increased 30% to $168.0 million, reflecting salesforce expansion and professional fees related to the company's redomiciliation from Bermuda to the UK.
• Redomiciliation: Completed in June 2024, changing the company's jurisdiction of incorporation from Bermuda to England and Wales.

Guidance, Outlook, and Risks

• Outlook: Management believes existing cash ($243.6 million) is sufficient to fund operations for at least the next 12 months. No specific financial guidance was provided in the text.
• Strategic Shifts:
  • Abiprubart: Development discontinued in Sjögren's Disease; exploring strategic alternatives.
  • Mavrilimumab: License with MedImmune terminated (effective May 2025); collaboration with Huadong in China faces termination if development activity does not resume.
  • KPL-387: Phase 1 initiated; Phase 2/3 in recurrent pericarditis planned for mid-2025.
• Key Risks:
  • Manufacturing Transfer: Significant risk associated with transferring ARCALYST drug substance manufacturing from Regeneron to Samsung Biologics. Failure could lead to supply shortages.
  • Commercialization: Reliance on third-party payors for reimbursement and specialty pharmacies for distribution.
  • Competition: Emerging competitors in recurrent pericarditis (e.g., CardiolRx, Ventyx Biosciences) and potential biosimilar competition.
  • Regulatory: Uncertainty regarding FDA policies under the new US administration and potential changes in healthcare legislation.

Investor Verification Checklist

• Manufacturing Transition Status: Verify the progress and regulatory approval status of the ARCALYST technology transfer to Samsung Biologics to assess supply chain risk.
• Abiprubart Termination Costs: Confirm the final financial impact of terminating abiprubart CDMO agreements (estimated $14M-$17M in Q1 2025).
• ARCALYST Profit Sharing: Monitor the correlation between ARCALYST sales growth and the resulting collaboration expense (profit share) paid to Regeneron.
• Huadong Collaboration: Track whether Huadong resumes material development activity for mavrilimumab in China to avoid contract termination.
• Cash Burn Rate: Assess the sustainability of the $243.6 million cash position given the increased R&D and SG&A spend and the lack of near-term large license milestones.